L & S Advisors Inc lifted its stake in CME Group Inc (NASDAQ:CME) by 124.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,888 shares of the financial services provider’s stock after acquiring an additional 6,042 shares during the period. L & S Advisors Inc’s holdings in CME Group were worth $2,113,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in CME. Geode Capital Management LLC grew its stake in CME Group by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 4,715,269 shares of the financial services provider’s stock worth $885,776,000 after buying an additional 537,917 shares during the last quarter. Moors & Cabot Inc. purchased a new position in CME Group during the 1st quarter worth $204,000. Victory Capital Management Inc. grew its stake in CME Group by 189.8% during the 1st quarter. Victory Capital Management Inc. now owns 98,067 shares of the financial services provider’s stock worth $16,140,000 after buying an additional 64,233 shares during the last quarter. Bbva Compass Bancshares Inc. grew its stake in CME Group by 41.1% during the 1st quarter. Bbva Compass Bancshares Inc. now owns 1,017 shares of the financial services provider’s stock worth $167,000 after buying an additional 296 shares during the last quarter. Finally, Cetera Investment Advisers grew its stake in CME Group by 31.9% during the 1st quarter. Cetera Investment Advisers now owns 1,447 shares of the financial services provider’s stock worth $239,000 after buying an additional 350 shares during the last quarter. 84.99% of the stock is owned by hedge funds and other institutional investors.
Several analysts have weighed in on the company. Zacks Investment Research downgraded CME Group from a “hold” rating to a “sell” rating and set a $158.00 price target on the stock. in a research note on Monday, May 27th. Deutsche Bank boosted their price target on CME Group from $224.00 to $240.00 and gave the company a “buy” rating in a research note on Friday, August 9th. UBS Group boosted their price target on CME Group from $191.00 to $214.00 and gave the company a “neutral” rating in a research note on Thursday, September 5th. Barclays boosted their price target on CME Group from $191.00 to $197.00 and gave the company an “overweight” rating in a research note on Thursday, May 23rd. Finally, BidaskClub downgraded CME Group from a “buy” rating to a “hold” rating in a research note on Thursday. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and seven have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $196.85.
In related news, CFO John W. Pietrowicz sold 2,500 shares of the company’s stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $201.30, for a total value of $503,250.00. Following the completion of the transaction, the chief financial officer now owns 32,854 shares of the company’s stock, valued at approximately $6,613,510.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sean Tully sold 7,200 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $223.13, for a total value of $1,606,536.00. Following the completion of the transaction, the insider now directly owns 19,923 shares of the company’s stock, valued at approximately $4,445,418.99. The disclosure for this sale can be found here. Insiders sold 59,626 shares of company stock worth $12,255,934 in the last 90 days. Company insiders own 1.20% of the company’s stock.
Shares of CME traded down $0.38 during mid-day trading on Friday, reaching $205.00. The company had a trading volume of 126,464 shares, compared to its average volume of 1,077,492. CME Group Inc has a 52-week low of $161.05 and a 52-week high of $224.91. The company has a quick ratio of 1.05, a current ratio of 1.05 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $73.56 billion, a P/E ratio of 30.06, a PEG ratio of 4.57 and a beta of 0.19. The stock has a 50 day moving average of $211.18 and a two-hundred day moving average of $191.03.
CME Group (NASDAQ:CME) last issued its earnings results on Wednesday, July 31st. The financial services provider reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.75 by $0.01. CME Group had a return on equity of 9.14% and a net margin of 39.36%. The firm had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.27 billion. During the same quarter in the prior year, the business earned $1.74 earnings per share. The company’s revenue was up 20.1% compared to the same quarter last year. On average, sell-side analysts expect that CME Group Inc will post 6.69 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 25th. Stockholders of record on Tuesday, September 10th will be paid a $0.75 dividend. The ex-dividend date is Monday, September 9th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.46%. CME Group’s payout ratio is 43.99%.
CME Group Company Profile
CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals, as well as fixed income products.
Recommended Story: How is diluted EPS different from basic EPS?
Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc (NASDAQ:CME).
Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.